Top

Published in:

01-11-2018 | Original Article

Impact of radiation-induced nausea and vomiting on quality of life

Authors: Caitlin Yee, Leah Drost, Liying Zhang, Bo Angela Wan, Vithusha Ganesh, May Tsao, Elizabeth Barnes, Mark Pasetka, Carlo DeAngelis, Edward Chow

Published in: Supportive Care in Cancer | Issue 11/2018

Abstract

Purpose

Radiotherapy-induced nausea and vomiting is a common side effect of radiotherapy. It is well-established that nausea and vomiting have a negative impact on quality of life, but the relative influence of each of symptom is infrequently reported. This study aimed to compare the effects of nausea and vomiting on quality of life in cancer patients receiving palliative radiotherapy.

Methods

The Functional Living Index-Emesis (FLIE) is a quality of life questionnaire developed in the chemotherapy-induced nausea and vomiting setting. The FLIE consists of 18 questions, half of which address nausea and half of which address vomiting. Three prospective studies on the efficacy of various anti-emetic medications conducted at our center used the FLIE to assess radiotherapy-induced nausea and vomiting at various time points during and after palliative radiotherapy. FLIE data from these three studies were combined for the present analysis. Univariate and multivariate analyses were conducted to assess the relationships between nausea and vomiting, time of FLIE completion, and patient-reported quality of life.

Results

Nausea and vomiting scores both decreased patients’ quality of life. Multivariate modeling showed that both symptoms significantly influenced patients’ ability to enjoy meals. Nausea was also associated with increased hardship for the patient, while vomiting imposed more difficulty on the patients’ loved ones.

Conclusions

Nausea and vomiting both significantly influence quality of life. Nausea seems to impact the patient more directly, whereas vomiting affects those closest to the patient.

Available only for authorised users

Poon M, Dennis K, Deangelis C, Chung H (2015) Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the functional living index—emesis (FLIE) quality-of-life tool. Support Care Cancer 25:2589–2598. https://doi.org/10.1007/s00520-015-2617-9 CrossRef

Dennis K, Maranzano E, De AC, Holden L (2011) Radiotherapy-induced nausea and vomiting. Expert Rev Pharmacoecon Outcomes Res 11:685–692CrossRef

Wong E, Pulenzas N, Bedard G, DeAngelis C, Zhang L, Tsao M, Danjoux C, Thavarajah N, Lechner B, McDonald R, Cheon PM, Chow E (2015) Ondansetron rapidly dissolving film for the prophylactic treatment of radiation-induced nausea and vomiting—a pilot study. Curr Oncol 22:199–210. https://doi.org/10.3747/co.22.2395 CrossRefPubMedPubMedCentral

Enblom A, Bergius Axelsson B, Steineck G, Hammar M, Börjeson S (2009) One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17:23–32. https://doi.org/10.1007/s00520-008-0445-x CrossRefPubMed

Feyer P, Jahn F, Jordan K (2013) Radiation induced nausea and vomiting. Eur J Pharmacol 722:1–7. https://doi.org/10.1016/j.ejphar.2013.09.069 CrossRef

Lindley CM, Hirsch JD, O’Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340. https://doi.org/10.1007/BF00434947 CrossRefPubMed

Dennis K, De Angelis C, Jon F et al (2014) Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study. Curr Oncol 21:e760–e767. https://doi.org/10.3747/co.21.2051 CrossRefPubMedPubMedCentral

Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, Bennett R (2013) Nausea still the poor relation in antiemetic therapy? The impact on cancer patients’ quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer 21:735–748. https://doi.org/10.1007/s00520-012-1574-9 CrossRefPubMed

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, On behalf of the ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232–243. https://doi.org/10.1093/annonc/mdq194 CrossRef

10.

de Souza CM, Visacri MB, Ferrari GB, Tuan BT, Costa APL, Barbosa CR, Lima CSP, Mazzola PG, Moriel P (2015) Nausea , vomiting and quality of life of patients with cancer undergoing antineoplastic treatment : an evaluation. Int J Pharm Pract 23:357–360. https://doi.org/10.1111/ijpp.12169 CrossRefPubMed

11.

Maranzano E, De Angelis V, Pergolizzi S et al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94:36–41. https://doi.org/10.1016/j.radonc.2009.11.001 CrossRefPubMed

12.

Feyer PC, Stewart AL, Titlbach OJ (1998) Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 6:253–260. https://doi.org/10.1007/s005200050163 CrossRefPubMed

13.

Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM (2003) Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395–1401. https://doi.org/10.1016/S0959-8049(03)00299-5 CrossRefPubMed

Title: Impact of radiation-induced nausea and vomiting on quality of life
Authors: Caitlin Yee
Leah Drost
Liying Zhang
Bo Angela Wan
Vithusha Ganesh
May Tsao
Elizabeth Barnes
Mark Pasetka
Carlo DeAngelis
Edward Chow
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4286-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2018

Investigating the prognostic ability of health-related quality of life on survival: a prospective cohort study of adults with lung cancer

Does implementation matter if comprehension is lacking? A qualitative investigation into perceptions of advance care planning in people with cancer

Muslim physicians and palliative care: attitudes towards the use of palliative sedation

Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study

Associated factors and costs of avoidable visits to the emergency department among cancer patients: 1-year experience in a tertiary care hospital in South Korea

Prehabilitation for surgical oncology patients: empowering patient volition

Keynote webinar | Spotlight on antibody–drug conjugates in cancer